Vergelijking

Cerebrolysin vs. Bremelanotide

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

96889-70-6

189691-06-3

Molecuulmassa

geen gegevens

1025.18 g/mol

Halfwaardetijd

geen gegevens

2.7 h

Sequentie

geen gegevens

Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH

Werkingsmechanisme

Cerebrolysin

Cerebrolysin is a mixture of low-molecular-weight peptides (predominantly below 10 kDa) and free amino acids obtained by enzymatic cleavage of lipid-free porcine brain proteins. The manufacturer and preclinical literature describe a neurotrophic and neuroprotective mode of action said to mimic endogenous neurotrophic factors; cell and animal models have reported effects on neuronal survival, synaptogenesis and anti-apoptotic signalling (including PI3K/Akt). Because it is a complex, incompletely characterised mixture, the precise mechanism in humans remains unclear.

Bremelanotide

Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Cerebrolysin	Bremelanotide
Oostenrijk	Op recept	—
Australië	—	Beperkt
CN	Op recept	—
Duitsland	Onduidelijk	Niet goedgekeurd
RU	Op recept	—
Verenigde Staten	Niet goedgekeurd	Op recept

Volledige vermeldingen

Cerebrolysin

Volledige vermelding →

Bremelanotide

Volledige vermelding →

Frequently asked questions

What is the difference between Cerebrolysin and Bremelanotide?: Cerebrolysin is classified as "Onderzoek (overig)", while Bremelanotide is classified as "Onderzoek (overig)". Cerebrolysin: Cerebrolysin (FPF-1070) is not a single peptide but a porcine-brain-derived preparation of low-molecular-weight peptides and free amino acids, produced by standardised enzymatic proteolysis. It is approved in several countries (including Austria, Russia and parts of Asia) for stroke, dementia and traumatic brain injury, but is not FDA-approved in the United States and not centrally approved by the EMA. Its efficacy is contested: Cochrane systematic reviews found no convincing benefit and flagged possible harm signals. Bremelanotide: Synthetic cyclic heptapeptide acting as a non-selective melanocortin-receptor agonist. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Cerebrolysin or Bremelanotide?: The highest available evidence level is "Humane RCT" for Cerebrolysin and "Humane RCT" for Bremelanotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Cerebrolysin and Bremelanotide in Germany and the United States?: Duitsland: Cerebrolysin — Onduidelijk, Bremelanotide — Niet goedgekeurd. Verenigde Staten: Cerebrolysin — Niet goedgekeurd, Bremelanotide — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Cerebrolysin

Bremelanotide

Oostenrijk

Op recept

—

Australië

—

Beperkt

Op recept

—

Duitsland

Onduidelijk

Niet goedgekeurd

Op recept

—

Verenigde Staten

Niet goedgekeurd

Op recept

Frequently asked questions

What is the difference between Cerebrolysin and Bremelanotide?

Cerebrolysin is classified as "Onderzoek (overig)", while Bremelanotide is classified as "Onderzoek (overig)". Cerebrolysin: Cerebrolysin (FPF-1070) is not a single peptide but a porcine-brain-derived preparation of low-molecular-weight peptides and free amino acids, produced by standardised enzymatic proteolysis. It is approved in several countries (including Austria, Russia and parts of Asia) for stroke, dementia and traumatic brain injury, but is not FDA-approved in the United States and not centrally approved by the EMA. Its efficacy is contested: Cochrane systematic reviews found no convincing benefit and flagged possible harm signals. Bremelanotide: Synthetic cyclic heptapeptide acting as a non-selective melanocortin-receptor agonist. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Cerebrolysin or Bremelanotide?

The highest available evidence level is "Humane RCT" for Cerebrolysin and "Humane RCT" for Bremelanotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Cerebrolysin and Bremelanotide in Germany and the United States?

Duitsland: Cerebrolysin — Onduidelijk, Bremelanotide — Niet goedgekeurd. Verenigde Staten: Cerebrolysin — Niet goedgekeurd, Bremelanotide — Op recept. These are factual summaries with source and review date on the individual pages.